CDC’s Worst-Case Coronavirus Model: 214 Million Infected, 1.7 Million Dead (Intelligencer)

A recent CDC projection estimated that the U.S. coronavirus epidemic could infect between 160 million and 214 million people over a period of more...
American BriVision

American BriVision (ABVC) Improves Working Capital and Reduce Debt.

American BriVision Announces Two Financial Transactions to Improve Working Capital and Reduce Debt FREMONT, CA, April 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – American...

FDA Authorizes Athersys (ATHX) to Initiate a Pivotal Clinical Trial!

FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome. (Editors note: a...
Corbus Pharma, Biotech Stock Review

Adding Corbis Pharma (CRBP) $5.55 to Watch List.

Running Clinical Trials Full Steam With $46 Million Banked in Late February. Not thinly, but lightly traded. Ready, locked and loaded. All of the common...
Athersys, Biotech Stock Review

Boo Ya. Brokerage Sets $12 Price Target for Athersys (ATHX) $2.96.

A major Wall Street firm that specializes in Bio and Medtech Companies has a $12 price target out on Athersys from one of its...

Adding Organicell (BPSR) $0.02 to the Watch List.

Organicell (BBSR). New client, studying now. Thinly, thinly traded and expectedly volatile on an intra-day basis. Like what we’ve read so far about their...
America BriVision, Biotech Stock Review

Adding American BriVision (ABVC) $2.00 to Watch List.

New client and an incubator, studying now. Thinly, thinly traded. We like what we've read so far about their vitreous substitute (eyeball fluid) called...
Internet Stock Review

Immunomedics (IMMU) up 100% Today or $2 Billion in Value & Stand Down VIII:

Bear Comments from Roubini, Jim Chanos, Jim Rogers and James A. Kostohryz Don't Be That Guy in Denial! Just like people who are in denial and don't...
Biotech Stock Review, Novellus, Citius

Citius (CTXR) and Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19

Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 - Novellus's patented mRNA-based cell-reprogramming...

New Report: Citius (CTXR) Trades 13 Million Shares on CoronaVirus and Candida Auris News.

Announces Mino-lok® Erdicates the Deadly and Untreatable C. Auris Bacteria.Announces License of Treatment for CoronaVirus Respiratory Failure. Read In Between the Lines. If the Mino-Lok®...

Latest article

Jeffrey Gundlach: Reckoning is Coming.

Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm. On 11 November 2020, Gundlach remarked in an interview with...

Who’s the Next Eric Sprott?

Eric Sprott, on Who is the Next Eric Sprott! To say Eric Sprott has left a legendary mark on the world of mining investment would...

Perpetua (PPTA) Raises $300 Million.

Not a bad day in Idaho. $300 million banked! We look at the dip as a buying opportunity, as does John Paulson & Co.,...